These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38746089)

  • 41. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.
    Abouantoun TJ; Castellino RC; MacDonald TJ
    J Neurooncol; 2011 Jan; 101(2):215-26. PubMed ID: 20524040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance.
    Ding Z; Kloss JM; Tuncali S; Tran NL; Loftus JC
    Neoplasia; 2020 Sep; 22(9):352-364. PubMed ID: 32629176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
    Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
    Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.
    Mukthavaram R; Ouyang X; Saklecha R; Jiang P; Nomura N; Pingle SC; Guo F; Makale M; Kesari S
    J Transl Med; 2015 Aug; 13():269. PubMed ID: 26283544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
    Jensen KV; Cseh O; Aman A; Weiss S; Luchman HA
    PLoS One; 2017; 12(12):e0189670. PubMed ID: 29253028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
    Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
    Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
    [No Abstract]   [Full Text] [Related]  

  • 49. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
    Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
    J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
    van Linde ME; Labots M; Brahm CG; Hovinga KE; De Witt Hamer PC; Honeywell RJ; de Goeij-de Haas R; Henneman AA; Knol JC; Peters GJ; Dekker H; Piersma SR; Pham TV; Vandertop WP; Jiménez CR; Verheul HMW
    Clin Cancer Res; 2022 Apr; 28(8):1595-1602. PubMed ID: 35165100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway.
    Dhruv HD; Roos A; Tomboc PJ; Tuncali S; Chavez A; Mathews I; Berens ME; Loftus JC; Tran NL
    J Neurooncol; 2016 Feb; 126(3):397-404. PubMed ID: 26559543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Alicke B; Plise EG; Cheong J; Jaochico A; Olivero AG; Sampath D; Wong S; Zhang X
    Xenobiotica; 2024 Feb; 54(2):64-74. PubMed ID: 38197324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
    Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
    Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma.
    Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z
    Front Immunol; 2022; 13():819515. PubMed ID: 35251000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
    Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
    J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma.
    Galimberti C; Piepoli T; Letari O; Artusi R; Persiani S; Caselli G; Rovati LC
    Am J Cancer Res; 2021; 11(7):3558-3574. PubMed ID: 34354860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
    Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
    PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.
    Mancini A; Colapietro A; Cristiano L; Rossetti A; Mattei V; Gravina GL; Perez-Montoyo H; Yeste-Velasco M; Alfon J; Domenech C; Festuccia C
    Front Oncol; 2022; 12():943064. PubMed ID: 36408162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.